IN2012DN00572A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00572A
IN2012DN00572A IN572DEN2012A IN2012DN00572A IN 2012DN00572 A IN2012DN00572 A IN 2012DN00572A IN 572DEN2012 A IN572DEN2012 A IN 572DEN2012A IN 2012DN00572 A IN2012DN00572 A IN 2012DN00572A
Authority
IN
India
Prior art keywords
compositions
treating
methods
provides
present
Prior art date
Application number
Other languages
English (en)
Inventor
Kristen Johnson
Lori Jennings
Peter Schultz
Original Assignee
Scripps Research Inst
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst, Irm Llc filed Critical Scripps Research Inst
Publication of IN2012DN00572A publication Critical patent/IN2012DN00572A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN572DEN2012 2009-07-14 2010-07-13 IN2012DN00572A (instruction)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14
PCT/US2010/041850 WO2011008773A2 (en) 2009-07-14 2010-07-13 Mesenchymal stem cell differentiation

Publications (1)

Publication Number Publication Date
IN2012DN00572A true IN2012DN00572A (instruction) 2015-06-12

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
IN572DEN2012 IN2012DN00572A (instruction) 2009-07-14 2010-07-13

Country Status (30)

Country Link
US (4) US9139633B2 (instruction)
EP (1) EP2453921B1 (instruction)
JP (1) JP5602850B2 (instruction)
KR (3) KR101590834B1 (instruction)
CN (2) CN102625830B (instruction)
AU (1) AU2010273570B2 (instruction)
BR (1) BR112012000914B8 (instruction)
CA (1) CA2767826C (instruction)
CL (1) CL2012000091A1 (instruction)
CO (1) CO6491059A2 (instruction)
CR (1) CR20120024A (instruction)
CU (1) CU24042B1 (instruction)
EA (1) EA023073B1 (instruction)
EC (1) ECSP12011604A (instruction)
ES (1) ES2541217T3 (instruction)
GT (1) GT201200011A (instruction)
IL (2) IL217383A (instruction)
IN (1) IN2012DN00572A (instruction)
MA (1) MA33423B1 (instruction)
MX (1) MX2012000707A (instruction)
MY (1) MY160951A (instruction)
NZ (1) NZ597306A (instruction)
PE (2) PE20160507A1 (instruction)
PL (1) PL2453921T3 (instruction)
PT (1) PT2453921E (instruction)
SG (1) SG177318A1 (instruction)
TN (1) TN2011000655A1 (instruction)
UA (1) UA104031C2 (instruction)
WO (1) WO2011008773A2 (instruction)
ZA (1) ZA201200078B (instruction)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597306A (en) * 2009-07-14 2014-03-28 Scripps Research Inst Mesenchymal stem cell differentiation
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN110446039B (zh) 2011-11-08 2022-01-11 韩国电子通信研究院 用于共享候选者列表的方法和装置
PT2864360T (pt) 2012-06-25 2018-01-05 The Brigham And Women`S Hospital Inc Terapêuticas dirigidas ao alvo
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
JO3564B1 (ar) * 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
AU2014236719B2 (en) 2013-03-15 2018-06-21 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
TN2016000441A1 (en) 2014-05-13 2018-04-04 Novartis Ag Compounds and compositions for inducing chondrogenesis.
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
CA3016764A1 (en) 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
CN109963579A (zh) * 2016-11-14 2019-07-02 诺华股份有限公司 用于治疗软骨损伤和关节炎的方法和组合物
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
US12257243B2 (en) 2018-12-06 2025-03-25 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN113015736B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
EP1078046A4 (en) 1998-05-12 2005-05-11 Human Genome Sciences Inc 97 HUMAN SECRETED PROTEINS
WO1999067382A2 (en) 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
JP2003531811A (ja) 1999-03-08 2003-10-28 ジェネンテック・インコーポレーテッド 血管形成及び心臓血管新生の促進又は阻害
ES2291198T3 (es) * 1999-07-20 2008-03-01 Genentech, Inc. Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
EP1927659B1 (en) * 2000-10-16 2010-01-27 Genetech, Inc. Wisp polypeptides and therapeutical applications thereof
US20040249141A1 (en) * 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CN1615440A (zh) 2001-11-16 2005-05-11 杰南技术公司 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法
US7157546B2 (en) * 2002-09-09 2007-01-02 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
EP1860186B1 (en) * 2003-03-10 2010-11-17 Japan Science And Technology Agency Method for distinguishing mesenchymal stem cells using different markers
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
CA2571315C (en) * 2004-06-21 2017-02-14 The Cleveland Clinic Foundation Ccr ligands for stem cell homing
US20110097330A1 (en) 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
WO2006127809A2 (en) 2005-05-24 2006-11-30 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
WO2008137641A2 (en) * 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
NZ597306A (en) * 2009-07-14 2014-03-28 Scripps Research Inst Mesenchymal stem cell differentiation
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل

Also Published As

Publication number Publication date
ECSP12011604A (es) 2012-06-29
PE20120570A1 (es) 2012-05-19
PT2453921E (pt) 2015-09-25
CR20120024A (es) 2012-06-11
IL217383A (en) 2016-08-31
IL247310B (en) 2018-04-30
CU24042B1 (es) 2014-11-27
BR112012000914A2 (pt) 2017-08-08
BR112012000914B1 (pt) 2021-04-06
SG177318A1 (en) 2012-03-29
CA2767826C (en) 2015-11-24
HK1164169A1 (en) 2012-09-21
KR20160015403A (ko) 2016-02-12
ZA201200078B (en) 2013-01-30
AU2010273570A1 (en) 2012-02-02
BR112012000914A8 (pt) 2017-12-19
TN2011000655A1 (en) 2013-05-24
US10064918B2 (en) 2018-09-04
US20190000922A1 (en) 2019-01-03
EP2453921B1 (en) 2015-05-27
US9139633B2 (en) 2015-09-22
KR101590834B1 (ko) 2016-02-12
CL2012000091A1 (es) 2012-10-26
MA33423B1 (fr) 2012-07-03
MX2012000707A (es) 2012-03-21
US20120177644A1 (en) 2012-07-12
US20160213748A1 (en) 2016-07-28
CN102625830A (zh) 2012-08-01
WO2011008773A2 (en) 2011-01-20
EA023073B1 (ru) 2016-04-29
CO6491059A2 (es) 2012-07-31
BR112012000914B8 (pt) 2021-05-25
EP2453921A2 (en) 2012-05-23
EA201200118A1 (ru) 2012-09-28
ES2541217T3 (es) 2015-07-16
PE20160507A1 (es) 2016-05-20
CA2767826A1 (en) 2011-01-20
GT201200011A (es) 2013-12-10
MY160951A (en) 2017-03-31
KR20180000337A (ko) 2018-01-02
US10555990B2 (en) 2020-02-11
CN102625830B (zh) 2016-03-02
CN105601728A (zh) 2016-05-25
AU2010273570B2 (en) 2014-07-03
US11241482B2 (en) 2022-02-08
KR20120029472A (ko) 2012-03-26
UA104031C2 (uk) 2013-12-25
US20200108122A1 (en) 2020-04-09
EP2453921A4 (en) 2012-12-19
PL2453921T3 (pl) 2015-11-30
WO2011008773A3 (en) 2011-08-25
JP2012533549A (ja) 2012-12-27
IL217383A0 (en) 2012-02-29
JP5602850B2 (ja) 2014-10-08
CN105601728B (zh) 2020-01-10
CU20120007A7 (es) 2013-02-26
NZ597306A (en) 2014-03-28

Similar Documents

Publication Publication Date Title
IN2012DN00572A (instruction)
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
PH12017501298A1 (en) Pesticidal compositions and processes related thereto
MX2009008222A (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
MY151551A (en) Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors
MX356282B (es) Composiciones y metodos que comprenden variantes de proteasa.
IN2012DN03883A (instruction)
MY172372A (en) Compositions and methods for lowering triglycerides
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
MX359327B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
MX2021011946A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
IL219107A (en) 2-Amino-5,5-Dipluoro-6,5-Dihydro-4 H-Oxazines as 1bace and / or 2bace inhibitors
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
IN2012DN02624A (instruction)
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
WO2011009890A3 (en) Use of azabicycloalkyl derivatives or pyrrolidine - 2 - one derivatives for the treatment or prevention of ataxia
WO2010141956A3 (en) Methods and compositions for the treatment of cancer
WO2010037095A3 (en) Agents and methods for the treatment of cancer
MX2010002950A (es) Metodos y composiciones para deteccion de ehrlichia chaffeensis (vlpt).